BioSpace News Archive

Biotech Bay

Alector Showcases Progress in Immuno-Neurology Clinical Programs and Research Portfolio at R&D Day

Reported results from analysis of the Phase 1b study of AL001 in patients with symptomatic FTD-GRN showing a statistically significant normalization in a number of disease-associated proteins and an initial trend of a decrease compared to baseline levels in plasma Neurofilament

December 16, 2019
·
7 min read
Policy

Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies

Eiger BioPharmaceuticals, Inc. announced that it has initiated submission of a New Drug Application for Lonafarnib for the treatment of Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies to the U.S. Food & Drug Administration under the Rolling Review Process.

December 16, 2019
·
7 min read
Biotech Beach

Adagio Medical Announces First Patient Enrollment in its iCLAS™ U.S. IDE Clinical Trial Evaluating Ultra-Low Temperature Cryoablation for Persistent Atrial Fibrillation

Adagio Medical, Inc. announced it has enrolled the first patient in its iCLAS™ Investigational Device Exemption trial.

December 16, 2019
·
2 min read
Drug Development

Positive results reaffirm plans to advance ATL1102 for DMD to Phase IIb trial

Antisense Therapeutics is pleased to advise that the data from all nine participants having completed their 24 weeks of dosing in the Phase 2 clinical trial of ANP’s immunomodulatory therapy

December 16, 2019
·
12 min read
Policy

Medical Negligence Survivors Launch Nov 2020 Ballot Measure Signature Drive For Proposal To Raise 1975 Compensation Cap That Was Never Adjusted

Juries are not told of the cap and injured patients cannot receive more than $250,000 for their quality of life and wrongful-death survivor damages, no matter how serious the injury or severe the medical negligence.

December 16, 2019
·
5 min read
Deals

Discovery Behavioral Health Acquires Casa Palmera

The San Diego Center Offers Evidence-based Treatment for Adults Dealing with Drugs and Alcohol Addiction

December 16, 2019
·
2 min read
Drug Development

Acer Therapeutics Announces Full Enrollment of Part B in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders

Part A Successfully Completed and Optimal Formulation of ACER-001 Identified Results of Part B Expected in Q1 2020 with a Planned NDA Submission in Q1 2021

December 16, 2019
·
8 min read
Deals

Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Dec. 16, 2019

Sientra, Inc., a medical aesthetics company, announced that on December 3, 2019, the Compensation Committee of the Company’s Board of Directors approved equity award grants under the Sientra, Inc. Inducement Plan to 15 new employees..

December 16, 2019
·
1 min read
Biotech Bay

Assembly Biosciences Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Assembly intends to use the net proceeds from the sale of the common stock to fund clinical trials, nonclinical studies, research and development and for general corporate purposes.

December 16, 2019
·
3 min read
Drug Development

Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH

The Phase 2a BALANCED study is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial in biopsy-confirmed patients with NASH.

December 16, 2019
·
5 min read